Literature DB >> 11536148

Metabolic control of recombinant monoclonal antibody N-glycosylation in GS-NS0 cells.

A E Hills1, A Patel, P Boyd, D C James.   

Abstract

Variable N-glycosylation at Asn(297) in the Fc region of recombinant therapeutic immunoglobulin G (IgG) molecules, specifically terminal galactosylation and sialylation, may affect both pharmacokinetic behavior and effector functions of recombinant therapeutic antibodies. We investigated the hypothesis that IgG Fc glycosylation can be controlled by manipulation of cellular nucleotide-sugar metabolism. In control cultures, N-glycans associated with the Fc domain of a recombinant humanized IgG1 produced by GS-NS0 cells in culture were predominantly biantennary, variably beta-galactosylated (average 0.3 mol galactose complex N-glycan(-1)) structures with no bisecting N-acetylglucosamine residues, sialylation, or alpha1,3-linked galactosylation evident. However, a variable proportion (5% to 15%) of high-mannose (Man5 to Man9) oligosaccharides were present. To manipulate the cellular content of the nucleotide sugar precursor required for galactosylation, UDP-Gal, we included either 10 mM glucosamine or 10 mM galactose in the culture medium. In the case of the former, a 17-fold increase in cellular UDP-N-acetylhexosamine content was observed, with a concomitant reduction (33%) in total UDP-hexose, although the ratio of UDP-Glc:UDP-Gal (4:1) was unchanged. Associated with these alterations in cellular UDP-sugar content was a significant reduction (57%) in the galactosylation of Fc-derived oligosaccharides. The proportion of high-mannose-type N-glycans (specifically Man5, the substrate for N-acetylglucosaminyltransferase I) at Asn(297) was unaffected. In contrast, inclusion of 10 mM galactose in culture specifically stimulated UDP-Gal content almost five-fold. However, this resulted in only a minimal, insignificant increase (6%) in beta1,4-galactosylation of Fc N-glycans. Sialylation was not improved upon the addition of the CMP-sialic acid (CMP-SA) precursor N-acetylmannosamine (20 mM), even with an associated 44-fold increase in cellular CMP-SA content. Analysis of recombinant IgG1 Fc glycosylation during batch culture showed that beta1,4-linked galactosylation declined slightly during culture, although, in the latter stages of culture, the release of proteases and glycosidases by lysed cells were likely to have contributed to the more dramatic drop in galactosylation. These data demonstrate: (i) the effect of steric hindrance on Fc N-glycan processing; (ii) the extent to which alterations in cellular nucleotide-sugar content may affect Fc N-glycan processing; and (iii) the potential for direct metabolic control of Fc N-glycosylation. Copyright 2001 John Wiley & Sons, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11536148     DOI: 10.1002/bit.10022

Source DB:  PubMed          Journal:  Biotechnol Bioeng        ISSN: 0006-3592            Impact factor:   4.530


  20 in total

1.  Comparison of LC and LC/MS methods for quantifying N-glycosylation in recombinant IgGs.

Authors:  Sandipan Sinha; Gary Pipes; Elizabeth M Topp; Pavel V Bondarenko; Michael J Treuheit; Himanshu S Gadgil
Journal:  J Am Soc Mass Spectrom       Date:  2008-07-16       Impact factor: 3.109

2.  Galactose supplementation enhance sialylation of recombinant Fc-fusion protein in CHO cell: an insight into the role of galactosylation in sialylation.

Authors:  Jintao Liu; Jie Wang; Li Fan; Xinning Chen; Dongdong Hu; Xiancun Deng; H Fai Poon; Haibin Wang; Xuping Liu; Wen-Song Tan
Journal:  World J Microbiol Biotechnol       Date:  2015-05-01       Impact factor: 3.312

3.  Electrospray ionization quadrupole ion-mobility time-of-flight mass spectrometry as a tool to distinguish the lot-to-lot heterogeneity in N-glycosylation profile of the therapeutic monoclonal antibody trastuzumab.

Authors:  Carola W N Damen; Weibin Chen; Asish B Chakraborty; Mike van Oosterhout; Jeffrey R Mazzeo; John C Gebler; Jan H M Schellens; Hilde Rosing; Jos H Beijnen
Journal:  J Am Soc Mass Spectrom       Date:  2009-08-07       Impact factor: 3.109

4.  Animal Cell Expression Systems.

Authors:  M Butler; U Reichl
Journal:  Adv Biochem Eng Biotechnol       Date:  2021       Impact factor: 2.635

5.  Exploiting metabolic glycoengineering to advance healthcare.

Authors:  Christian Agatemor; Matthew J Buettner; Ryan Ariss; Keerthana Muthiah; Christopher T Saeui; Kevin J Yarema
Journal:  Nat Rev Chem       Date:  2019-09-06       Impact factor: 34.035

6.  Ultrafast and high-throughput N-glycan analysis for monoclonal antibodies.

Authors:  Xiaoyu Yang; Sunnie Myung Kim; Richard Ruzanski; Yuetian Chen; Sarath Moses; Wai Lam Ling; Xiaojuan Li; Shao-Chun Wang; Huijuan Li; Alexandre Ambrogelly; Daisy Richardson; Mohammed Shameem
Journal:  MAbs       Date:  2016-04-15       Impact factor: 5.857

7.  Comprehensive manipulation of glycosylation profiles across development scales.

Authors:  Sven Loebrich; Elisa Clark; Kristina Ladd; Stefani Takahashi; Anna Brousseau; Seth Kitchener; Robert Herbst; Thomas Ryll
Journal:  MAbs       Date:  2018-10-22       Impact factor: 5.857

8.  Intact transferrin and total plasma glycoprofiling for diagnosis and therapy monitoring in phosphoglucomutase-I deficiency.

Authors:  Nurulamin Abu Bakar; Nicol C Voermans; Thorsten Marquardt; Christian Thiel; Mirian C H Janssen; Hana Hansikova; Ellen Crushell; Jolanta Sykut-Cegielska; Francis Bowling; Lars MØrkrid; John Vissing; Eva Morava; Monique van Scherpenzeel; Dirk J Lefeber
Journal:  Transl Res       Date:  2018-05-10       Impact factor: 7.012

Review 9.  Antibody-mediated protection against Ebola virus.

Authors:  Erica Ollmann Saphire; Sharon L Schendel; Bronwyn M Gunn; Jacob C Milligan; Galit Alter
Journal:  Nat Immunol       Date:  2018-10-17       Impact factor: 25.606

10.  An HPLC-MALDI MS method for N-glycan analyses using smaller size samples: application to monitor glycan modulation by medium conditions.

Authors:  Michael P Gillmeister; Noboru Tomiya; Scott J Jacobia; Yuan C Lee; Stephen F Gorfien; Michael J Betenbaugh
Journal:  Glycoconj J       Date:  2009-12       Impact factor: 2.916

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.